{"id":37821,"date":"2025-07-23T15:25:09","date_gmt":"2025-07-23T07:25:09","guid":{"rendered":"https:\/\/flcube.com\/?p=37821"},"modified":"2025-07-23T15:25:09","modified_gmt":"2025-07-23T07:25:09","slug":"shanghai-kehua-bioengineering-subsidiary-receives-two-ivd-certificates-from-nmpa","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=37821","title":{"rendered":"Shanghai Kehua Bioengineering Subsidiary Receives Two IVD Certificates from NMPA"},"content":{"rendered":"\n<p>China-based Shanghai Kehua Bioengineering Co., Ltd. (KHB) (<a href=\"https:\/\/www.google.com\/finance\/quote\/002022:SHE\">SHE: 002022<\/a>) announced on July 23, 2025, that its controlling subsidiary, Suzhou Tianlong Science and Technology Co., Ltd., has received two in vitro diagnostic (IVD) medical device registration certificates from China&#8217;s National Medical Products Administration (NMPA). The approved products are the Respiratory Syncytial Virus Nucleic Acid Detection Kit (Fluorescent PCR Method) and the Adenovirus Nucleic Acid Detection Kit (Fluorescent PCR Method). Both certificates are valid until July 16, 2030.<\/p>\n\n\n\n<p><strong>Product Details<\/strong><br>Both products are designed for the in vitro qualitative detection of nucleic acids from their respective viruses in human pharyngeal swab samples. These certifications mark a significant milestone in the company&#8217;s expansion of its diagnostic capabilities.<\/p>\n\n\n\n<p><strong>Business Impact<\/strong><br>The company stated that the approval of these related products will enrich its product line and have a positive impact on its business development. This expansion into new diagnostic areas is expected to enhance Kehua Bio-engineering&#8217;s market position and customer offerings.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/\u79d1\u534e\u751f\u7269\uff1a\u5173\u4e8e\u4ea7\u54c1\u83b7\u5f97\u533b\u7597\u5668\u68b0\u6ce8\u518c\u8bc1\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u79d1\u534e\u751f\u7269\uff1a\u5173\u4e8e\u4ea7\u54c1\u83b7\u5f97\u533b\u7597\u5668\u68b0\u6ce8\u518c\u8bc1\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-c2198a60-91af-449b-ba5e-c3eb3e7105d7\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/\u79d1\u534e\u751f\u7269\uff1a\u5173\u4e8e\u4ea7\u54c1\u83b7\u5f97\u533b\u7597\u5668\u68b0\u6ce8\u518c\u8bc1\u7684\u516c\u544a.pdf\">\u79d1\u534e\u751f\u7269\uff1a\u5173\u4e8e\u4ea7\u54c1\u83b7\u5f97\u533b\u7597\u5668\u68b0\u6ce8\u518c\u8bc1\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/\u79d1\u534e\u751f\u7269\uff1a\u5173\u4e8e\u4ea7\u54c1\u83b7\u5f97\u533b\u7597\u5668\u68b0\u6ce8\u518c\u8bc1\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-c2198a60-91af-449b-ba5e-c3eb3e7105d7\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China-based Shanghai Kehua Bioengineering Co., Ltd. (KHB) (SHE: 002022) announced on July 23, 2025, that&#8230;<\/p>\n","protected":false},"author":1,"featured_media":37824,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,22],"tags":[611,15,2785],"class_list":["post-37821","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-medical-device","tag-kehua-bioengineering","tag-product-approvals","tag-tianlong-science-and-technology"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Shanghai Kehua Bioengineering Subsidiary Receives Two IVD Certificates from NMPA - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Shanghai Kehua Bioengineering Co., Ltd. (KHB) (SHE: 002022) announced on July 23, 2025, that its controlling subsidiary, Suzhou Tianlong Science and Technology Co., Ltd., has received two in vitro diagnostic (IVD) medical device registration certificates from China&#039;s National Medical Products Administration (NMPA). The approved products are the Respiratory Syncytial Virus Nucleic Acid Detection Kit (Fluorescent PCR Method) and the Adenovirus Nucleic Acid Detection Kit (Fluorescent PCR Method). Both certificates are valid until July 16, 2030.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=37821\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shanghai Kehua Bioengineering Subsidiary Receives Two IVD Certificates from NMPA\" \/>\n<meta property=\"og:description\" content=\"China-based Shanghai Kehua Bioengineering Co., Ltd. (KHB) (SHE: 002022) announced on July 23, 2025, that its controlling subsidiary, Suzhou Tianlong Science and Technology Co., Ltd., has received two in vitro diagnostic (IVD) medical device registration certificates from China&#039;s National Medical Products Administration (NMPA). The approved products are the Respiratory Syncytial Virus Nucleic Acid Detection Kit (Fluorescent PCR Method) and the Adenovirus Nucleic Acid Detection Kit (Fluorescent PCR Method). Both certificates are valid until July 16, 2030.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=37821\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-23T07:25:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2308.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37821#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37821\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Shanghai Kehua Bioengineering Subsidiary Receives Two IVD Certificates from NMPA\",\"datePublished\":\"2025-07-23T07:25:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37821\"},\"wordCount\":170,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37821#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2308.webp\",\"keywords\":[\"Kehua Bioengineering\",\"Product approvals\",\"TianLong Science and Technology\"],\"articleSection\":[\"Company\",\"Medical Device\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37821#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37821\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=37821\",\"name\":\"Shanghai Kehua Bioengineering Subsidiary Receives Two IVD Certificates from NMPA - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37821#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37821#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2308.webp\",\"datePublished\":\"2025-07-23T07:25:09+00:00\",\"description\":\"China-based Shanghai Kehua Bioengineering Co., Ltd. (KHB) (SHE: 002022) announced on July 23, 2025, that its controlling subsidiary, Suzhou Tianlong Science and Technology Co., Ltd., has received two in vitro diagnostic (IVD) medical device registration certificates from China's National Medical Products Administration (NMPA). The approved products are the Respiratory Syncytial Virus Nucleic Acid Detection Kit (Fluorescent PCR Method) and the Adenovirus Nucleic Acid Detection Kit (Fluorescent PCR Method). Both certificates are valid until July 16, 2030.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37821#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37821\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37821#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2308.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2308.webp\",\"width\":1080,\"height\":608,\"caption\":\"Shanghai Kehua Bio-engineering Subsidiary Receives Two IVD Certificates from NMPA\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37821#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shanghai Kehua Bioengineering Subsidiary Receives Two IVD Certificates from NMPA\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Shanghai Kehua Bioengineering Subsidiary Receives Two IVD Certificates from NMPA - Insight, China&#039;s Pharmaceutical Industry","description":"China-based Shanghai Kehua Bioengineering Co., Ltd. (KHB) (SHE: 002022) announced on July 23, 2025, that its controlling subsidiary, Suzhou Tianlong Science and Technology Co., Ltd., has received two in vitro diagnostic (IVD) medical device registration certificates from China's National Medical Products Administration (NMPA). The approved products are the Respiratory Syncytial Virus Nucleic Acid Detection Kit (Fluorescent PCR Method) and the Adenovirus Nucleic Acid Detection Kit (Fluorescent PCR Method). Both certificates are valid until July 16, 2030.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=37821","og_locale":"en_US","og_type":"article","og_title":"Shanghai Kehua Bioengineering Subsidiary Receives Two IVD Certificates from NMPA","og_description":"China-based Shanghai Kehua Bioengineering Co., Ltd. (KHB) (SHE: 002022) announced on July 23, 2025, that its controlling subsidiary, Suzhou Tianlong Science and Technology Co., Ltd., has received two in vitro diagnostic (IVD) medical device registration certificates from China's National Medical Products Administration (NMPA). The approved products are the Respiratory Syncytial Virus Nucleic Acid Detection Kit (Fluorescent PCR Method) and the Adenovirus Nucleic Acid Detection Kit (Fluorescent PCR Method). Both certificates are valid until July 16, 2030.","og_url":"https:\/\/flcube.com\/?p=37821","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-07-23T07:25:09+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2308.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=37821#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=37821"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Shanghai Kehua Bioengineering Subsidiary Receives Two IVD Certificates from NMPA","datePublished":"2025-07-23T07:25:09+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=37821"},"wordCount":170,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=37821#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2308.webp","keywords":["Kehua Bioengineering","Product approvals","TianLong Science and Technology"],"articleSection":["Company","Medical Device"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=37821#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=37821","url":"https:\/\/flcube.com\/?p=37821","name":"Shanghai Kehua Bioengineering Subsidiary Receives Two IVD Certificates from NMPA - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=37821#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=37821#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2308.webp","datePublished":"2025-07-23T07:25:09+00:00","description":"China-based Shanghai Kehua Bioengineering Co., Ltd. (KHB) (SHE: 002022) announced on July 23, 2025, that its controlling subsidiary, Suzhou Tianlong Science and Technology Co., Ltd., has received two in vitro diagnostic (IVD) medical device registration certificates from China's National Medical Products Administration (NMPA). The approved products are the Respiratory Syncytial Virus Nucleic Acid Detection Kit (Fluorescent PCR Method) and the Adenovirus Nucleic Acid Detection Kit (Fluorescent PCR Method). Both certificates are valid until July 16, 2030.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=37821#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=37821"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=37821#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2308.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2308.webp","width":1080,"height":608,"caption":"Shanghai Kehua Bio-engineering Subsidiary Receives Two IVD Certificates from NMPA"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=37821#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Shanghai Kehua Bioengineering Subsidiary Receives Two IVD Certificates from NMPA"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2308.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37821","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=37821"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37821\/revisions"}],"predecessor-version":[{"id":37825,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37821\/revisions\/37825"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/37824"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=37821"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=37821"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=37821"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}